HC Deb 27 May 1988 vol 134 cc413-5W
Mr. Gareth Wardell

To ask the Secretary of State for Social Services what evidence his Department holds about the role of Carbadox as a carcinogen in humans.

Mrs. Currie

The Department holds information from animal test data provided by the manufacturers, Pfizer Ltd.; also the following published scientific reports:

  1. 1. Bentin L, Preller E, and Kowalsi B. Antimicrob. Agents Chemotherap. 20. 336–343, 1981.
  2. 2. Yoshimura H, Nakamura M, Koeda T, and Yoshikawa K. Mut. Res. 90: 49–55, 1981.
  3. 3. Voogd C E, Van der Stel J J, and Jacobs J J J A A. Mut. Res. 78: 233–242, 1980.
  4. 4. Negishi T, Tanaka K, and Hayatsu H. Chem. Pharm. But. 28: 1347–1349, 1980.
  5. 5. Ohta T, Moriya M, Kaneda Y, Watanabe K, Miyazawa T, Sugiyama F, and Shirasu Y. Mut. Res. 77: 21–30, 1980.
  6. 6. Shirasu Y, Moriya M, and Kato K. Mut. Res. 53: 261, 1978. (Abstract).
  7. 7. Oud J L, Reutlinger A H H, and Brangcr J. Mut. Res. 68: 179–182, 1979.
  8. 8. Cihak R, Srb V, and Vontorkava M. Mut. Res. 116: 129–135, 1983.
  9. 9. Sykora and Vortel 1986. Natal study of the Carcinogenicity of Cyadox and Carbadox. Biol. Vet. Chem. (Praha) 22, 53–62.

The Department holds sufficient evidence to establish that this compound is a mutagen and a carcinogen, both in laboratory tests and in living animals.

Mr. Gareth Wardell

To ask the Secretary of State for Social Services what evidence his Department has that the compounds of Carbadox and Olaquindox are mutagens.

Mrs. Currie

The Department holds information from animal test data provided by the manufacturers, Pfizer and Bayer respectively, and the following published scientific reports:

  1. 1. Bentin L., Prellar E. and Kowalski B (1981): Mutagenicity of quindoxin, its matabolites and two substituted Quinoxaline-di-N-oxides. Antimicrob. Agents and Chemother. 20 (3): 336–343.
  2. 2. Cihak R., Srb V. and Vontorkova M. (1983). Cytogenetic effects of quixoxaline-1,4-dioxide-type growth-promoting agents. I. Micro-nucleus test in rats. Mutat. Res. 116: 129–135.
  3. 3. Cihak R. and Vontorkova M. (1983). Cytogenetic effects of quinoxaline-1,4-dioxide-type growth-promoting agents. II. Metaphase analysis in mice. Mutat. Res. 117: 311–316.
  4. 4. Cihak R. and Vontorkova M. (1985). Cytogenetic effects of quinoxaline-1,4-dioxide-type growth-promoting agents. III. Transplacental micronucleus test in mice. Mutat. Res. 144 (2): 81–84.
  5. 5. English A. R. and Dunegan C. M. (1970). Quinoxaline-1,4-di-N-oxides. I. Inhibition of deoxyribonucleic acid synthesis in Escherichia coli by 2,3-dihydroxymethyl-quinoxaline-1,4-di-N -oxide (34481). Proc. Soc. Expl. Biol. Med. 133: 398–400.
  6. 6. Suter W., Rosselet A. and Knussel F. (1978). Mode of action of quindoxin and substituted quinoxaline-di-N-oxides on Escherichia coli. Antimicrob. Agents and Chemotherap. 13 (5): 770–783.
  7. 7. Voogd C. E., van der Stel J. J. and Jacobs J. J. J. A. A. (1980). The Mutagenic action of quindoxin, carbadox, olaquindox and some other N-oxides on bacteria and yeast. Mutat. Res. 78: 233–242, 1980.
  8. 8. Yoshimura H., Nakamura M. and Koeda T. (1981). Mutagenic activities of carbadox and olaquindox—growth promoters for pigs. Mutat. Res. 90: 49–55.
  9. 9. Negishi T., Tanaka K., Hayatsu H. (1980). Mutagenicity of carbadox and several quinoxaline-1,4-dioxide derivative. Chem. Pharm. Bull. 28, 1347–1349.
  10. 10. Windholz M., Budavari S., Blumetti R. F., Otterbein E. S. (Eds) (1983). The Merck Index, Merck and Co. Inc. Rahway, New Jersey.
  11. 11. Sykora A. and Vortel V. (1986). Natal Study of the Carcinogenicity of Cyadox and Carbadox. Biol. Vet. Chem. (Praha): 22, pages 53–62.
  12. 12. Ohta T., Moriya M., Kaneda Y., Watanabe K., Miyazawa T., Sugiyama F., and Shirasu Y. Mut. Res. 77: 21–30, 1980.
  13. 13. Shirasu Y., Moriya M., and Kato K. Mut Res. 53: 261, 1978.
    14. 415
  14. 14. Oud J. L., Reutlinger A. H. H. and Branger J. Mut. Res. 68: 179–182, 1979.

The Department holds sufficient evidence to establish that these compounds are mutagens, both in laboratory tests and in living animals.

Forward to